Efficacy and safety of hemodialysis strategies for pregnant women with chronic kidney disease: Systematic review.
Ana Luiza Cabrera MartimbiancoRoberta de Fátima Carreira MoreiraRafael Leite PachecoCarolina de Oliveira Cruz LatorracaAna Paula Pires Dos SantosPatrícia LogulloRachel RieraPublished in: Seminars in dialysis (2022)
Pregnancy in chronic kidney disease (CKD) women is relatively rare, and the less risky choice of hemodialysis is unknown. The objective of this systematic review was to identify, systematically evaluate and summarize the available evidence on the efficacy and safety of hemodialysis strategies for pregnant CKD women. Sensitive search strategies were applied to six databases without data or language restrictions. Comparative (randomized and non-randomized) studies were prioritized. Two reviewers independently selected, extracted, and critically evaluated data from studies. The risk of bias assessment was performed using the ROBINS-I tool, considering the study design (non-randomized comparative observational studies). The certainty of the evidence was assessed using the GRADE approach. From 7210 references identified, six retrospective cohort studies were included (576 women). The effects of intensive hemodialysis (over 20 h/week) are uncertain for maternal and neonatal mortality (Peto odds ratio [OR] 0.85; 95% confidence interval [95% CI] 0.26-2.80), miscarriage (Peto OR 0, 38; 95% CI 0.12-1.23), stillbirths (Peto OR 0, 56; 95% CI 0.13-2.31), preterm birth (Peto OR 0.87; 95% CI 0.33-2.28), low birth weight (Peto OR 0.71; 95% CI 0.20-2.50) and congenital anomalies rates. The certainty of the evidence was very low due to studies methodological limitations and effect estimates imprecision. The uncertainty about intensive versus conventional hemodialysis effects for pregnant women with CKD and the imprecision in the estimated effects precludes any recommendation. The strategy choice must consider treatment availability, costs, and maternal social aspects until future studies provide more reliable evidence. PROSPERO CRD42021259237.
Keyphrases
- chronic kidney disease
- end stage renal disease
- preterm birth
- pregnancy outcomes
- pregnant women
- low birth weight
- systematic review
- peritoneal dialysis
- placebo controlled
- double blind
- open label
- polycystic ovary syndrome
- case control
- phase iii
- meta analyses
- human milk
- preterm infants
- big data
- clinical trial
- healthcare
- electronic health record
- mental health
- gestational age
- birth weight
- cross sectional
- phase ii
- cervical cancer screening
- cardiovascular disease
- randomized controlled trial
- skeletal muscle
- decision making
- breast cancer risk
- machine learning
- cardiovascular events
- current status
- adipose tissue
- type diabetes
- artificial intelligence
- coronary artery disease